The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Open accessAbstract
Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase 2/3 trials with chronic-phase chronic myeloid leukemia with or without BCR-ABL mutations after prior imatinib. Among 1043 patients, 39% had a preexisting BCR-ABL mutation, including 48% of 805 patients with imatinib resistance or suboptimal response. Sixty-threedifferent BCR-ABL mutations affecting 49 amino acids were detected at baseline, with G250, M351, M244, and F359 most frequently affected. After 2 years of follow-up, dasatinib treatment of imatinib-resistant patients with or without a mutation resulted in notable response rates (complete cytogenetic response: 43% vs 47%) and durable progression-free survival (70% vs 80%). High response rates were achieved with different mutations except T315I, including highly imatinib-resistant mutations in the P-loop region. Impaired responses were observed with some mutations with a dasatinib median inhibitory concentration (IC50) greater than 3nM; among patients with mutations with lower or unknown IC50, efficacy was comparable with those with no mutation. Overall, dasatinib has durable efficacy in patients with or without BCR-ABL mutations. All trials were registered at http://www.clinicaltrials.gov as NCT00123474, NCT00101660, and NCT00103844.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Self-citationHughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Self-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Self-citationMolecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Self-citationBranford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Self-citationTokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 643
O'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Self-citationSoverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 589
Self-citationChronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Metadata
- Authors
- Müller, M. C., Cortes, J. E., Kim, D.-W., Druker, B. J., Erben, P., Pasquini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., Mukhopadhyay, J., & Hochhaus, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-12-03
- Volume
- 114
- Issue
- 24
- Pages
- 4944-4953
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2091423586
- Cited by
- 290
- References
- 36
- FWCI
- 22.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. https://app.cochat.ai/papers/10.1182/blood-2009-04-214221
- The paper
- Müller, M. C., Cortes, J. E., Kim, D.-W., Druker, B. J., Erben, P., Pasquini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., Mukhopadhyay, J., & Hochhaus, A. (2009). Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. https://doi.org/10.1182/blood-2009-04-214221
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.